Chimerix Announces Inducement Grant of Stock Options
Chimerix (NASDAQ:CMRX), a prominent biopharmaceutical company, has announced a notable inducement award for a newly hired employee. This grant includes non-statutory stock options totaling 150,000 shares of the company's common stock, underscoring Chimerix's dedication to attracting top talent in the competitive biotech industry.
Details of the Stock Options Grant
This award, approved by the Compensation Committee of Chimerix’s Board of Directors, serves as a vital incentive that complies with Nasdaq Listing Rule 5635(c)(4). The stock options feature an exercise price that aligns with the closing trading price on the grant date, ensuring that the new employee's potential rewards are directly linked to the company’s market performance.
Vesting Schedule and Plan Terms
The granted stock options come with a generous 10-year term. They will vest over a four-year period, with one-fourth of the options becoming available on the one-year anniversary of the employee's hire date. The remaining options will vest in equal monthly installments over the following three years, encouraging long-term commitment and engagement from the new team member.
Chimerix's Commitment to Innovation
Chimerix is focused not only on developing its workforce but also on its core mission: creating innovative medicines that greatly improve the lives of patients facing serious illnesses. One of its significant programs is the clinical-stage therapy ONC201, which targets H3 K27M-mutant glioma, showcasing Chimerix's strategic approach to addressing unmet medical needs.
Advancements in Clinical Trials
In line with its commitment to research and development, Chimerix is conducting Phase 1 dose escalation studies for ONC206. These studies are essential for evaluating safety and pharmacokinetic data, which are crucial for future treatment advancements. By concentrating on these important areas, Chimerix aims to make a meaningful impact in the biopharmaceutical field.
Company Contacts
For additional inquiries or information regarding the inducement grant and company updates, please contact:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
Frequently Asked Questions
What is the purpose of the inducement grant by Chimerix?
The inducement grant is designed to attract and retain talented employees, ensuring their potential rewards are aligned with the company's performance.
How many stock options were granted to the new employee?
A total of 150,000 shares of Chimerix’s common stock were awarded as non-statutory stock options.
What is the vesting schedule for the stock options?
One-fourth of the options will vest on the one-year anniversary of the hire date, with the remaining options vesting in equal monthly installments over the next three years.
Which clinical programs is Chimerix currently pursuing?
Chimerix is actively developing ONC201 for H3 K27M-mutant glioma and conducting studies for ONC206 to assess safety and pharmacokinetic data.
How does Chimerix aim to improve patients' lives?
Chimerix is dedicated to developing and advancing therapies that provide significant enhancements in treatment options for patients facing serious health challenges.
